CN104352974A - 一种含朱砂莲的治疗糖尿病的中药组合物 - Google Patents
一种含朱砂莲的治疗糖尿病的中药组合物 Download PDFInfo
- Publication number
- CN104352974A CN104352974A CN201410632774.6A CN201410632774A CN104352974A CN 104352974 A CN104352974 A CN 104352974A CN 201410632774 A CN201410632774 A CN 201410632774A CN 104352974 A CN104352974 A CN 104352974A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- diabetes
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 235000006386 Polygonum aviculare Nutrition 0.000 title abstract 3
- 241001377695 Polygonum arenastrum Species 0.000 title 1
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 235000014375 Curcuma Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 2
- 244000292697 Polygonum aviculare Species 0.000 abstract 2
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 abstract 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 11
- 201000001421 hyperglycemia Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000256856 Vespidae Species 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000046585 Aristolochia clematitis Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000164439 Curcuma angustifolia Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000004360 Dioscorea zingiberensis Nutrition 0.000 description 1
- 241001678283 Dioscorea zingiberensis Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域，涉及一种中药组合物，具体涉及一种含朱砂莲的治疗糖尿病的中药组合物。本发明的治疗糖尿病的中药组合物是由以下重量配比的药用原料制备而成：广枣5～15份、蜂房5～15份、桑葚1～5份、朱砂莲0.6～3.5份、佛手0.6～3.5份、姜黄0.6～3.5份。本发明治疗糖尿病的中药组合物，6味药用原料按配方比例组合治疗糖尿病具有协同增效功能，用于治疗糖尿病疗效显著且对患者身体无副作用。
Description
技术领域
本发明属于医药技术领域，涉及一种中药组合物，具体涉及一种含朱砂莲的治疗糖尿病的中药组合物。
背景技术
糖尿病是一组以高血糖为特征的代谢性疾病，是我国发病率高，危害严重的流行病之一。糖尿病时长期存在的高血糖，导致各种组织，特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍，引发各种糖尿病并发症。据统计，糖尿病并发症的死亡率仅次于心血管病、脑血管病和肿瘤，居第四位。中国糖尿病患者数量已接近4000万人，居世界第三，与20世纪80年代的0.7％相比，增长了5倍。糖尿病可由遗传和环境因素相互作用而引起，常见症状有多饮、多尿、多食以及消瘦等。糖尿病可引起身体多***的损害；引起胰岛素绝对或相对分泌不足以及靶组织细胞对胰岛素敏感性降低；引起蛋白质、脂肪、水和电解质等一系列代谢紊乱综合征，其中以高血糖为主要标志。目前治疗糖尿病的药很多，尤其是西药，但副作用大，而中成药效果不够显著。
发明内容
本发明的目的提供一种含朱砂莲的治疗糖尿病的中药组合物，该中药组合物疗效好、对人身体副作用小。
为了实现上述发明目的，本发明提供了以下技术方案：
一种含朱砂莲的治疗糖尿病的中药组合物，是由以下重量配比的药用原料制备而成：广枣5～15份、蜂房5～15份、桑葚1～5份、朱砂莲0.6～3.5份、佛手0.6～3.5份、姜黄0.6～3.5份。所述各种药用原料均为符合国家或地方标准规定的中药材。
优选的，上述药用原料中，广枣所占重量比例为7～12份。更优选的，广枣所占重量比例为9份。
优选的，上述药用原料中，蜂房所占重量比例为7～12份。更优选的，蜂房所占重量比例为9份。
优选的，上述药用原料中，桑葚所占重量比例为2～4份。更优选的，桑葚所占重量比例为3份。
优选的，上述药用原料中，朱砂莲所占重量比例为1.4～2.6份。更优选的，朱砂莲所占重量比例为2份。
优选的，上述药用原料中，佛手所占重量比例为1.4～2.6份。更优选的，佛手所占重量比例为2份。
优选的，上述药用原料中，姜黄所占重量比例为1.4～2.6份。更优选的，姜黄所占重量比例为2份。
本发明的治疗糖尿病的中药组合物，可以按照常规的中药提取方法提取药用原料的活性组分，如加水煎煮，或用乙醇或乙醇的水溶液回流提取并收集提取液并浓缩；再加上药学上可接受的载体或/和辅料，如淀粉、糊精、微晶纤维、可压性淀粉、硬脂酸镁、微粉硅胶、蔗糖、羧甲基淀粉钠、羟丙基甲基纤维素、植物油、卵磷脂、聚乙二醇、丙二醇、尼泊金乙酯等，制成药剂学上适宜的剂型，如颗粒剂、片剂、硬胶囊、口服液、软胶囊、滴丸、水泛丸等。
与现有技术相比，本发明的有益效果：
本发明治疗糖尿病的中药组合物，是发明人基于祖国医学对糖尿病的发病机理的认识，根据自己多年临床经验，先从众多中药中确定一系列对治疗糖尿病有效的中药，再经临床反复验证而筛选出来的。其中，广枣，为漆树科植物南酸枣的干燥成熟果实；味甘、酸，性平；具有行气活血，养心安神的作用；用于气滞血瘀，胸痹作痛，心悸气短，心神不安等症。蜂房，别名露蜂房、马蜂窝、蜂巢、野蜂窝、黄蜂窝、百穿之巢；为胡蜂科昆虫果马蜂或异腹胡蜂的巢；甘，平；归胃经；具有祛风，功毒，杀虫，止痛的功效；用于龋齿牙痛，疮疡肿毒，乳痈，瘰疬，皮肤顽癣，鹅掌风等症。桑葚，为桑科植物桑的干燥果穗；甘、酸，寒；归心、肝、肾经；具有补血滋阴、生津润燥的功效；用于眩晕耳鸣，心悸失眠，须发早白，津伤口渴，内热消渴，血虚便秘等症。朱砂莲，别名背蛇生、躲蛇生；为马兜铃科马兜铃属植物朱砂莲，以根状茎入药；苦、辛，寒；有小毒；具有清热解毒、消肿止痛的功效；用于肠炎，痢疾，尾、十二指肠溃疡，咽喉肿痛，毒蛇咬伤，痈疖肿毒，外伤出血等症。佛手，别名佛手柑、手柑；为芸香科柑橘属植物佛手的干燥果实；辛、苦、酸，温；归肝、脾、肺经；具有舒肝理气，和胃止痛的功效；用于肝胃气滞，胸胁胀痛，胃脘痞满，食少呕吐等症。姜黄，别名黄姜、毛姜黄、宝鼎香、黄丝郁金；为姜科植物姜黄的干燥根茎；辛、苦，温；归脾、肝经；具有破血行气、通经止痛的功效；用于胸胁剌痛，闭经，癓瘕，风湿肩臂疼痛，跌扑肿痛等症。上述6味中草药按配方比例混合后，按照常规的中药提取方法提取药用原料的活性组分后得到本发明的治疗糖尿病的中药组合物。其中的6味药按配方比例组合后，治疗糖尿病具有协同增效的功能，能显著降低血糖、血脂浓度，提高血流量和抗氧化功效，治疗糖尿病效果显著且无毒副作用。
具体实施方式
下面结合试验例及具体实施方式对本发明作进一步的详细描述。但不应将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明内容所实现的技术均属于本发明的范围。
实施例1
本实施例的治疗糖尿病的中药组合物，是由以下重量配比的药用原料制备而成：广枣9g、蜂房9g、桑葚3g、朱砂莲2g、佛手2g、姜黄2g。
上述药用原料的提取方法：按配方比例取药用原料，向药用原料中加水煎煮2次，2次煎煮的用水体积依次为药用原料体积的10倍和8倍，2次煎煮时间依次为1.5小时和1小时，每次煎煮后过滤并收集滤液；合并2次滤液，得到实施例1药用原料的提取液，将实施例1药用原料的提取液浓缩至相对密度1.20(80℃)，得实施例1的提取物。
向上述提取物中加入提取物2倍重量的可溶性淀粉，制粒、干燥，分装成袋，得到实施例1治疗糖尿病的中药组合物颗粒剂。
实施例2
本实施例的治疗糖尿病的中药组合物，是由以下重量配比的药用原料制备而成：广枣15g、蜂房5g、桑葚5g、朱砂莲0.6g、佛手3.5g、姜黄0.6g。
上述药用原料的提取方法同实施例1。
实施例3
本实施例的治疗糖尿病的中药组合物，是由以下重量配比的药用原料制备而成：广枣12g、蜂房8g、桑葚4g、朱砂莲3g、佛手2.4g、姜黄2.2g。
上述药用原料的提取方法同实施例1。
对比例
本实施例的治疗糖尿病的中药组合物，是由以下重量配比的药用原料制备而成：广枣9g、蜂房9g、桑葚3g、佛手2g、姜黄2g。
上述药用原料的提取方法同实施例1。
药效学试验证明：
为了证实本发明药物的疗效和安全性，发明人进行了药效学和毒性试验考察。所采用的研究方法及试验结果如下：
1、试验材料
(1)药物及试剂：
根据实施例1制备的本发明中药组合物；
根据对比例制备的对比例中药组合物；
四氧嘧啶，SIGMA Co.生产；
葡萄糖测定试剂盒，由北京化工厂生产；
降糖灵，市售。
(2)动物：昆明种小鼠，由四川抗菌素研究所实验动物中心提供。
(3)仪器：VZS-723分光光度计，电子天平等。
2、试验方法与结果：
(一)本发明药物对四氧嘧啶性糖尿病小鼠高血糖的影响
(1)、造高血糖模型与分组
取体重25±1g昆明种雄性小鼠80只，禁食不禁水。3小时后，尾静脉注射四氧嘧啶生理盐水注射液85mg/kg(0.5ml/只)造成高血糖模型，另将15只体重25±1g昆明种雄性小鼠尾静脉注射等量生理盐水(0.5ml/只)，做为正常对照动物。72小时后，将上述小鼠禁食不禁水10小时；然后自其眼眶取血，葡萄糖氧化酶法测每只小鼠血糖浓度。
从80只注射四氧嘧啶生理盐水注射液的小鼠中选择血糖高于200mg/dL且血糖值相近的60只，随机分为4组，即模型组、本发明药物组、对照组1及降糖灵组，每组15只。
(2)、给药、测血糖浓度
五组小鼠分别按下述方法灌胃给药和生理盐水：对本发明药物组灌胃本发明实施例1制备的中药组合物，用药总剂量：7g/kg(生药材)；对降糖灵组灌胃降糖灵，用药总剂量：80mg/kg；对对照组1灌胃本发明对比例制备的中药组合物，用药总剂量：7g/kg(生药材)；对模型组灌服等溶媒量的生理盐水；生理盐水组灌服等溶媒量的生理盐水。
连续给药10天，给药期间及前后观察各组的小鼠的摄食、活动及***情况均无异常情况发生。于第10天给药1小时后，眼眶取血，测空腹血糖浓度(禁食不禁水10小时，方法同前述)。比较对照组1与模型组之间，各给药组之间差异，结果见表1。
表1
注：表1中，与模型组比较:▲▲▲P＜0.001,▲▲P＜0.05，▲P＞0.05。
表1中实验结果表明：小鼠静脉注射四氧嘧啶72小时后，小鼠高血糖造模成功，其血糖浓度显著高于生理盐水组。用本发明药物组连续给药10天后，小鼠血糖浓度降为387.4±33.1mg/dL，比模型组的小鼠血糖浓度449.6±41.2mg/dL低62mg/dL左右。且本发明药物组的统计结果相对于模型组的的统计结果P＜0.05，具有显著性差异，本发明的药物组对四氧嘧啶性糖尿病小鼠高血糖的降血糖治疗效果好；且小鼠给药期间及前后无不良反应，本发明的治疗糖尿病的中药组合物治疗糖尿病对患者身体副作用小。
而对照组1连续给药10天后，小鼠血糖浓度为417.3±95.5mg/dL，比模型组的小鼠血糖浓度449.6±41.2mg/dL低32mg/dL左右；比本发明药物组小鼠血糖浓度降的统计值387.4±33.1mg/dL高30mg/dL左右；且对照组1的统计结果相对于模型组的统计结果P＞0.05，无显著性差异。故得知，对比例制备的中药组合物对四氧嘧啶性糖尿病小鼠高血糖的降血糖治疗效果差。
综上，本发明治疗糖尿病的中药组合物，治疗糖尿病疗效好、见效快且对身体无副作用，6味药用原料按配方比例组合后，具有协同增效功能；缺少任意组分，中药组合物治疗糖尿病的疗效都会明显降低，如上述药效学试验中，对照组1的治疗效果相对于本发明药物组的疗效明显降低，且本发明的治疗糖尿病的中药组合物治疗糖尿病对患者身体副作用小。
Claims (10)
1.一种含朱砂莲的治疗糖尿病的中药组合物，其特征在于：它是由以下重量配比的药用原料制成：广枣5～15份、蜂房5～15份、桑葚1～5份、朱砂莲0.6～3.5份、佛手0.6～3.5份、姜黄0.6～3.5份。
2.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：广枣所占重量比例为7～12份。
3.根据权利要求2所述的治疗糖尿病的中药组合物，其特征在于：广枣所占重量比例为9份。
4.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：蜂房所占重量比例为7～12份。
5.根据权利要求4所述的治疗糖尿病的中药组合物，其特征在于：蜂房所占重量比例为9份。
6.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：桑葚所占重量比例为2～4份。
7.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：朱砂莲所占重量比例为1.4～2.6份。
8.根据权利要求7所述的治疗糖尿病的中药组合物，其特征在于：朱砂莲所占重量比例为2份。
9.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：佛手所占重量比例为1.4～2.6份。
10.根据权利要求1所述的治疗糖尿病的中药组合物，其特征在于：姜黄所占重量比例为1.4～2.6份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410632774.6A CN104352974A (zh) | 2014-11-11 | 2014-11-11 | 一种含朱砂莲的治疗糖尿病的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410632774.6A CN104352974A (zh) | 2014-11-11 | 2014-11-11 | 一种含朱砂莲的治疗糖尿病的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352974A true CN104352974A (zh) | 2015-02-18 |
Family
ID=52520347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410632774.6A Pending CN104352974A (zh) | 2014-11-11 | 2014-11-11 | 一种含朱砂莲的治疗糖尿病的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352974A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511888A (zh) * | 2016-05-18 | 2017-03-22 | 安徽康乐美生物科技有限公司 | 一种预防或者治疗糖尿病的中药组合物、制剂及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724065A (zh) * | 2005-07-15 | 2006-01-25 | 中国人民解放军第三军医大学第二附属医院 | 治疗糖尿病的药物及其制备方法 |
| CN1814262A (zh) * | 2005-12-22 | 2006-08-09 | 陈宝贵 | 一种治疗糖尿病的药物及其制备方法 |
| CN101455789A (zh) * | 2007-12-14 | 2009-06-17 | 雷海云 | 一种降糖利尿的中药制剂及其制备方法 |
| CN101472600A (zh) * | 2007-07-31 | 2009-07-01 | 中国中医科学院西苑医院 | 一种调节血糖、血脂的药物组合物及其制备方法和用途 |
-
2014
- 2014-11-11 CN CN201410632774.6A patent/CN104352974A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724065A (zh) * | 2005-07-15 | 2006-01-25 | 中国人民解放军第三军医大学第二附属医院 | 治疗糖尿病的药物及其制备方法 |
| CN1814262A (zh) * | 2005-12-22 | 2006-08-09 | 陈宝贵 | 一种治疗糖尿病的药物及其制备方法 |
| CN101472600A (zh) * | 2007-07-31 | 2009-07-01 | 中国中医科学院西苑医院 | 一种调节血糖、血脂的药物组合物及其制备方法和用途 |
| CN101455789A (zh) * | 2007-12-14 | 2009-06-17 | 雷海云 | 一种降糖利尿的中药制剂及其制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511888A (zh) * | 2016-05-18 | 2017-03-22 | 安徽康乐美生物科技有限公司 | 一种预防或者治疗糖尿病的中药组合物、制剂及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101972338B (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
| CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
| CN102302563A (zh) | 一种治疗慢性肾功能衰竭的中药组合物及其制备方法 | |
| CN104027529A (zh) | 一种调节血脂、血压、血糖的中药组合物及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN104288644A (zh) | 一种治疗脾虚的药物组合物及其制备方法 | |
| CN103223111B (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
| CN103690784B (zh) | 治疗糖尿病肾病合并高血压肾病的中药组合物及制备方法 | |
| CN102885975B (zh) | 一种治疗糖尿病的中药组合物 | |
| CN105148220A (zh) | 一种治疗脾肾阳虚型眩晕的中药及制备方法 | |
| CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
| CN101623485A (zh) | 一种丹莪妇康颗粒 | |
| CN104436022A (zh) | 一种含苦金盆的治疗糖尿病的中药组合物 | |
| CN103393938B (zh) | 一种降血糖的中药组合物 | |
| CN108186821B (zh) | 一种治疗神经性头痛的中药组合物及其制备方法和用途 | |
| CN104352974A (zh) | 一种含朱砂莲的治疗糖尿病的中药组合物 | |
| CN102949681B (zh) | 一种预防或治疗感冒的组合物及其制备方法 | |
| CN104352672A (zh) | 一种含龟板的治疗糖尿病的中药组合物 | |
| CN100486621C (zh) | 一种治疗偏头痛的中药片剂及其制备方法 | |
| CN113058013A (zh) | 一种中药组合物及其制备方法和应用 | |
| CN103989940A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN104337898B (zh) | 一种含郁李仁的治疗痛风的中药组合物 | |
| CN104435141B (zh) | 一种含鬼箭羽的治疗糖尿病的中药组合物 | |
| CN103520684A (zh) | 一种降血糖的中药复合物 | |
| CN103705868B (zh) | 一种治疗甲状腺功能亢进的药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150218 |
|
| RJ01 | Rejection of invention patent application after publication |